IMMUTEP Ltd
Business
Immutep Ltd is a late-stage biotechnology company developing LAG-3 related immunotherapies for cancer and autoimmune disease. It offers clinical-stage product candidates including eftilagimod alfa (a soluble LAG-3Ig APC agonist), LAG-3 antibodies and agonists, small‑molecule programs, and research reagents, supported by manufacturing partners. Its business is organized around therapeutic development segments—oncology and autoimmune programs—managed through in‑house R&D, clinical development and partnered/licensed assets. Immutep pursues global clinical development and distribution via collaborations, licensing agreements and third‑party manufacturers across Europe, North America, Asia and Australia.
Summary from filing dated 2025-10-24
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-61.43M |
| Total assets | $156.98M |
| Total liabilities | $13.35M |
| Stockholders' equity | — |
| Operating cash flow | — |